Revolution Medicines company profile
Company profile
Revolution Medicines has 883 employees and is headquartered in Redwood City, United States.
Revolution Medicines, Inc. has been headquartered in Redwood City, California, since it was incorporated in 2014. The clinical-stage precision oncology company develops targeted therapies for RAS-addicted cancers. Its pipeline is built around RAS(ON) inhibitors that bind RAS variants and can be used alone or in combination with other RAS(ON) inhibitors, RAS companion inhibitors or other therapeutic agents. Daraxonrasib and zoldonrasib are part of a phase 3 registrational trial testing their combination in patients with first-line pancreatic ductal adenocarcinoma (1L PDAC), while elironrasib G12C is in early clinical development for solid tumors. Further development candidates include RMC-5127, RMC-0708 and RMC-8839.
In the fiscal year ended December 2025, the company reported a net loss of USD 1.1 billion. It employed 883 people.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 700 Saginaw Drive, 94063, Redwood City
- Employees
- 883
- Chief executive
- Mark Goldsmith
- Founded
- 2014
- Fiscal year
- January - December
- Listing
- RVMD · NASDAQ
- Currency
- USD
- ISIN
- US76155X1000
- Website
- revmed.com
Revolution Medicines and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Revolution MedicinesRVMD | United States | $37.27B | 883 | -853.0% | — |
| Royalty PharmaRPRX | United States | $39.4B | 100 | 64.4% | 45.4 |
| BeOne MedicinesONC | United States | $46.98B | 12,000 | 17.8% | 52.7 |
| Roivant SciencesROIV | United States | $28.64B | 721 | -3,226.3% | — |
| InsmedINSM | United States | $26.96B | 1,664 | -41.7% | — |
| IncyteINCY | United States | $24.36B | 2,844 | 32.2% | 61.0 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
